Clinical trial NCT02009488: Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
Official title: A Double-Blind, Placebo-Controlled, Randomized, Parallel Groups, Multicenter Study to Investigate the Effects of Canagliflozin on Insulin Sensitivity, Hepatic Fat Content and Beta Cell Function in Subjects With Type 2 Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetes Mellitus, Type 2
Keywords: Diabetes Mellitus, Type 2
Metformin
Canagliflozin
INVOKANA®
Insulin sensitivity
DPP-4 inhibitor
dipeptidyl peptidase-4
Lead sponsor: Janssen Research & Development, LLC
Sponsor class: INDUSTRY
First posted: 2013-12-12
Enrollment: 59
Sex: ALL
Minimum age (years): 25
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess changes from baseline in insulin sensitivity, hepatic fat content and beta cell function after approximately 24-25 weeks of treatment with canagliflozin compared to placebo in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic (blood sugar) control on metformin monotherapy or on combination therapy with metformin and a dipeptidyl peptidase-4 (DPP-4) inhibitor.

Detailed description: This is a double-blind (neither physician nor participants knows the treatment that the participant receives), randomized (the study medication is assigned by chance), placebo-controlled (an inactive substance is compared with a medication to test whether the medication has a real effect in a clinical study), parallel-groups study which will be conducted at 2 clinical research centers (CRC) in the US. Approximately 56 participants, ages 25-70 years, with T2DM inadequately controlled on either metformin monotherapy or combination therapy with metformin and a DPP-4 inhibitor, will be enrolled. The study has 3 phases: pre-treatment, double-blind treatment, and post-treatment.

Pre-Treatment Phase will consist of a screening visit (Week -5), 14 days Single- Blind Placebo Run-in period, followed by 14 days of Single-Blind Placebo Baseline Period, during which participants will be randomized (1:1) to one of 2 treatment groups, either canagliflozin or placebo. Double-Blind Treatment Phase begins on Day 1, and ends at approximately Week 25, during which participants will be assessed at least biweekly at outpatient visits or by telephone contact. Canagliflozin treatment will be initiated at 100 mg/day, with up-titration to 300 mg/day, consistent with the approved INVOKANA® US Prescribing Information 2013. During post-treatment phase, a follow-up visit will occur within approximately 28 days after the last dose of study drug.

At baseline and after 24 weeks of treatment with canagliflozin, hepatic and peripheral insulin sensitivity will be assessed using tracer labeled euglycemic clamp technique; hepatic fat content will be determined using 1H nuclear magnetic resonance spectroscopy (MRS); beta cell function (insulin secretion rate and beta cell glucose sensitivity) will be assessed during mixed meal tolerance test (MMTT); substrate oxidation and energy production rates will be measured using indirect calorimetry during euglycemic clamp and MMTT.

During the study, participants will remain on their stable dose regimens of metformin or combination metformin DPP-4 inhibitor therapy, unless the investigator considers dose modification to be medically necessary. The total study duration for each participant participating in this study will be up to approximately 34 weeks.

Eligibility criteria: Inclusion Criteria:

* Must have a diagnosis of T2DM for at least 3 months and be on either metformin monotherapy at a stable dose of \>=1,000 mg per day or on combination therapy of metformin \>=1,000 mg per day and a DPP-4 inhibitor at stable daily doses for at least 12 weeks prior to screening with an HbA1c of \>=7.0% and \<= 9.5% at Screening
* Fasting plasma glucose \>=120 mg/dL and \<=240 mg/dL at the Week -4 visit
* Fasting fingerstick glucose \>=120 mg/dL and \<=240 mg/dL performed at clinical research center on Day -14
* Must be medically stable on the basis of clinical laboratory tests performed at screening

Exclusion Criteria:

* Has a history of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or β-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
* Has claustrophobia or anxiety, related to previous negative experiences with magnetic resonance imaging procedures which cannot be managed with an anxiolytic drug
* Has a history of brittle or labile glycemic control, with widely varying glucose measurements
* Has proliferative diabetic retinopathy (based on an eye examination within one year prior to Screening), currently receiving or requiring treatment
* Has a history of 1 or more severe hypoglycemic episodes within 6 months before screening
* Has history of hereditary glucose-galactose malabsorption or primary renal glucosuria.

Primary outcomes:
measure: Change from baseline in hepatic insulin sensitivity
timeFrame: Baseline, 25 weeks
measure: Change from baseline in peripheral tissue insulin sensitivity
timeFrame: Baseline, 25 weeks
measure: Change from baseline in liver fat content, determined using magnetic resonance spectroscopy (MRS)
timeFrame: Baseline, 25 weeks
measure: Change from baseline in insulin secretion rate (ISR) during mixed-meal tolerance test (MMTT)
timeFrame: Baseline, 25 weeks
measure: Change from baseline in beta-cell glucose sensitivity, determined as a slope of ISR vs. plasma glucose concentration during MMTT
timeFrame: Baseline, 25 weeks
Secondary outcomes:
measure: Changes from baseline in substrate oxidation and energy production rates during MMTT and euglycemic clamp
timeFrame: Baseline, 25 weeks
measure: Changes from baseline in insulin clearance during MMTT and euglycemic clamp
timeFrame: Baseline, 25 weeks
measure: Change from baseline in suppression of free fatty acids (FFAs) during euglycemic clamp
timeFrame: Baseline, 25 weeks
measure: Changes from baseline in basal and postprandial plasma glucagon, FFAs and β-hydroxybutyrate during MMTT
timeFrame: Baseline, 25 weeks
measure: Change from baseline in renal threshold for glucose (RTG), estimated using an MMTT-based method
timeFrame: Baseline, 25 weeks
Other outcomes:
Locations:
city: San Diego, La Jolla
country: United States
state: California
city: Gainesville
country: United States
state: Florida
Study officials:
affiliation: Janssen Research & Development, LLC
name: Janssen Research & Development, LLC Clinical Trial
role: STUDY_DIRECTOR
References: